Results 71 to 80 of about 590 (119)

Safety of Tralokinumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-blind, Placebo-controlled Phase 2 and Phase 3 Trials

, 2022
BACKGROUND: Tralokinumab is a fully human monoclonal antibody that neutralizes the activity of interleukin-13, a key pathogenic driver of atopic dermatitis (AD).
de Bruin-Weller, Marjolein, Silverberg, Jonathan I, Warren, Richard B, Papp, Kim, Thyssen, Jacob P, Merola, Joseph F, Reich, Kristian, Thyssen, Jacob P., Warren, Richard B., Simpson, Eric L, Girolomoni, Giampiero, Wollenberg, Andreas, Simpson, Eric L., Silverberg, Jonathan I., Zachariae, Rebecca, Staumont, Delphine, Staumont-Sallé, Delphine, Olsen, Christiana K., Olsen, Christiana K, Merola, Joseph F.   +19 more
core   +1 more source

Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series [PDF]

The recent approval of novel targeted therapies that included two biologics (dupilumab and tralokinumab) and three small molecules consisting of Janus kinase (JAK) inhibitors (abrocitinib, baricitinib and upadacitinib) has profoundly changed the long-
S. RIBERO, Di Nardo, Lucia, Teofila Seremet, Giulia Coscarella, Bianchi, L., M. MUNERA CAMPOS, Argenziano, Giuseppe, Argenziano, G., Monica Munera Campos, Ippoliti, E., Manuel, Giampiero Girolomoni, Ippoliti, Elena, Lucia Di Nardo, Chiricozzi, A., Maurelli, M., N. GORI, A. BALATO, Nardo, Lucia, Di , Silvia Mariel Ferrucci, Ribero, S., Seremet, T., Anna Balato, Ribero, Simone, Flaminia Antonelli, Girolomoni, Giampiero, Carrascosa, J.M., Marzano, Angelo Valerio, Balato, A., G. GIROLOMONI, Peris, Ketty, A. CHIRICOZZI, Carrascosa Jose, Andrea Chiricozzi, C. CONRAD, Coscarella, G., Balato, Anna, K. PERIS, L. MASTORINO, G. ARGENZIANO, Marzano, A.V., C. PAGANINI, Marco Galluzzo, Luca Bianchi, Ferrucci, Silvia Mariel, M. MAURELLI, Bianchi, Luca, Carrascosa, Jose Manuel, Galluzzo, M., E. IPPOLITI, J. M. CARRASCOSA, Antonelli, Flaminia, T. SEREMET, G. COSCARELLA, F. ANTONELLI, M. GALLUZZO, Munera , Curdin Conrad, Peris, K., L. DI NARDO, Maurelli, Martina, Ketty Peris, Ferrucci, S.M., Martina Maurelli, Di Nardo, L., Chiricozzi, Andrea, E. V. DI BRIZZI, Galluzzo, Marco, Seremet, Teofila, Ortoncelli, M., M. TALAMONTI, N. MACAGNO, Conrad, Curdin, Michela Ortoncelli, Jose Manuel Carrascosa, S. M. FERRUCCI, Ortoncelli, Michela, Girolomoni, G., M. ORTONCELLI, A. V. MARZANO, Elena Ippoliti, Munera Campos, M., Simone Ribero, Angelo Valerio Marzano, Gori, Niccolò, L. BIANCHI, Giuseppe Argenziano, Niccolò Gori, Gori, N., Conrad, C., Coscarella, Giulia, Munera Campos, Monica, Campos, Monica, Antonelli, F., Macagno, Nicole, Mastorino, Luca, Gori, Niccolo'   +97 more
core   +1 more source

Dupilumab in patients with bullous pemphigoid and concomitant atopy

Frontiers in Pharmacology
BackgroundBullous pemphigoid (BP) and atopic dermatitis (AD) are chronic inflammatory skin diseases that may share overlapping immunopathogenic mechanisms, particularly a type 2 immune response.
Katerina Jobst, Stephan R. Künzel, Stephan R. Künzel, Stefan Beissert, Susanne Abraham   +4 more
doaj   +1 more source

Tralokinumab as a cost-saving treatment option for adults and adolescents with moderate-to-severe atopic dermatitis enrolled in US health insurance plans: a budget impact analysis

Journal of Comparative Effectiveness Research
Background: Atopic dermatitis (AD) is a chronic and burdensome condition that causes intense itching and painful skin lesions and affects around 10% of adults and adolescents across the US.
Reece Grindley, Linnea Houde, Aseel Bin Sawad, Sanjeev Balu, Shannon Schneider   +4 more
doaj   +1 more source

Real‑World Experience of 1 Year of Tralokinumab Treatment in Adult Patients with Atopic Dermatitis: A Single-Center Retrospective Study

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic inflammatory disease requiring long-term management. Biologic therapies have emerged as systemic treatment options for AD, and real-world evidence (RWE) of their use is needed to inform optimal treatment ...
Adrian O. Rodriguez, Caid Sterling Smith
doaj   +1 more source

Tralokinumab and Acitretin for the Treatment of Lamellar Ichthyosis

This case report describes a man in his 30s who presented with severe and generalized congenital ichthyosis and was treated with a combination of tralokinumab and ...
Baeck, Marie, De Greef, Axel
core   +1 more source

Supplementary Material - ECZTEND Interim Analysis Manuscript (2 years tralokinumab treatment)

, 2022
Supplementary Information to accompany and support the manuscript: Long-term 2-Year Safety and Efficacy of Tralokinumab in Adults with Moderate-to-severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-label Extension Trial.THIS DATASET IS ...
Whitaker, M (via Mendeley Data), Whitaker, Meredith   +1 more
core   +1 more source

Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic, inflammatory skin condition in which interleukin (IL)-13 is a key driver. Tralokinumab, an IL-13-targeting monoclonal antibody, has demonstrated efficacy and a favorable safety profile in patients with ...
April W. Armstrong, Ahmed Ameen, Silvia Ferrucci, José-Juan Pereyra-Rodríguez, Michael J. Cork, Cory Rubin, Abel Jarell, Alessandra Narcisi, Pierre-Andre Becherel, Jennifer Beecker, Teodora Festini, Ida Vittrup, Frank Vinther, Diamant Thaçi   +13 more
doaj   +1 more source

Case Report: Differential response to IL-13 inhibition: lebrikizumab following primary tralokinumab failure in atopic dermatitis

Frontiers in Medicine
BackgroundAtopic dermatitis is a chronic inflammatory skin disorder driven largely by type 2 immune pathways, with interleukin-13 (IL-13) playing a central role in disease pathogenesis.
Shukry Abdi, Clare Bailey, Andreea Cifrea   +2 more
doaj   +1 more source

Injection site reactions after dupilumab or tralokinumab for atopic dermatitis

Journal of Dermatological Treatment
Background: Injection site reaction (ISR) is a local phenomenon defined as a constellation of symptoms, including swelling, erythema, pruritus, and pain around the site of injection.Objective: ISR is reported as a frequent adverse event after ...
Fabrizio Martora, Cataldo Patruno, Silvia D’Ascenzo, Maddalena Napolitano   +3 more
doaj   +1 more source